Summit Therapeutics

Summit Therapeutics, Inc. a biopharmaceutical company, which discovers, develops, and commercializes medicines to treat infectious diseases. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Menlo Park, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Summit Therapeutics reports strong financials and strategic Akeso partnership

Summit Therapeutics showcased strong financials, promising clinical trial results, and a strategic partnership with Akeso for ivonescimab, positioning the company for growth.
While facing challenges around licensing agreements and international trial data acceptance, Summit's focus on oncology and global collaborations presents opportunities for future success.
With a solid financial foundation, innovative pipeline, and strategic vision, Summit is well-positioned to navigate challenges, capitalize on opportunities, and drive value for stakeholders.

Summit Therapeutics secures $5B deal for ivonescimab, shifts to oncology

Summit Therapeutics made a strategic move with a $5 billion transaction for ivonescimab, signaling a shift towards oncology-focused R&D.
While challenges exist in transitioning away from anti-infectives, Summit's strong financial position and Phase III progress offer promising opportunities.
The company's commitment to innovative therapies and strategic partnerships sets the stage for potential growth and market success.

Summit Therapeutics reports stable finances and progress in Phase III trials

Summit Therapeutics showcased resilience with a strong cash position despite reporting a net loss in Q2 2023.
The company's progress in Phase III trials and positive patient response data offer promise for future growth.
While facing challenges in trial execution and financial pressures, Summit has opportunities to advance its pipeline and attract investor support.

Summit Therapeutics advances ivonescimab in Q3 with strong financials

Summit Therapeutics is making significant strides in advancing ivonescimab for solid tumors, supported by strong financials and strategic partnerships. While facing challenges in differentiation and competitive landscape, the company is well-positioned to seize opportunities for growth and innovation. With a focus on operational excellence and clinical trial progress, Summit remains poised for future success.

Summit Therapeutics excels in Q4 with Ivonescimab progress and challenges

Summit Therapeutics showcased strong performance and financial stability, driven by advancements in Ivonescimab's trials and partnerships.
While facing challenges such as upcoming regulatory actions and timeline constraints, the company remains poised to leverage opportunities for market differentiation and growth.

Summit Therapeutics advances ivonescimab in oncology, eyes Phase III data

Summit Therapeutics made significant progress in Q1 2024, bolstered by strong financials and strategic collaborations. The company's focus on ivonescimab's potential in oncology, along with upcoming data releases, positions it for future success. Managing R&D expenses and leveraging key partnerships will be critical for sustained growth.

Summit Therapeutics advances ivonescimab with strong financial backing and collaborations

Summit Therapeutics made significant progress in clinical trials and regulatory milestones for ivonescimab, supported by strong financials and strategic collaborations.
While facing challenges in data disclosure and operational management, the company has opportunities to drive growth through further trial success and partnerships.
Overall, Summit Therapeutics is well-positioned to capitalize on its strengths and navigate challenges to unlock future opportunities in the competitive biopharmaceutical landscape.
Investors should monitor the company's continued progress in trials, partnerships, and financial management for insights into its long-term growth potential.

Summit Therapeutics advances ivonescimab with strong financial backing and global trials

Summit Therapeutics demonstrated strong performance in advancing ivonescimab, supported by robust financial management and operational efficiency.
While facing challenges in regulatory uncertainties and managing expenses, the company has opportunities to leverage positive trial outcomes and strategic expansions.
Overall, Summit Therapeutics' progress with ivonescimab presents a promising outlook for accelerated development and market growth in diverse tumor settings.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Miami, FL.

MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) announced that the Journal of the American Medical Association (JAMA) published a manuscript titled, “Ivonescimab Plus Chemotherapy in Non-Small Cell Lung Cancer with EGFR Variant: A Randomized Clinical Trial.” The publication is based on the results of HARMONi-A, a single region, multi-center, Phase III study conducted in China sponsored by Akeso, Inc. (Akeso, HKEX Code: 9926.HK), with data gener.

Ivonescimab Manuscript for HARMONi-A Clinical Trial Results Published in JAMA

MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) announced that, on May 24, 2024, our partner, Akeso Inc. (Akeso, HKEX Code: 9926.HK), received marketing authorization in China from the National Medical Products Administration (NMPA). The approval is based on the positive dataset associated with HARMONi-A, a single region, multi-center, Phase III study conducted in China sponsored by Akeso with data generated and analyzed by Akeso. HARMONi-A eva.

Ivonescimab in Combination with Chemotherapy Approved in China by NMPA for 2L+ EGFRm NSCLC based on HARMONi-A Clinical Trial: Positive Trend Observed in Overall Survival towards Ivonescimab Plus Chemotherapy

The shares of Summit Therapeutics Inc (NASDAQ:SMMT) appear to be headed for a minor correction after yesterday's skyrocket.

Biotech Stock Volatile After Upbeat Trial data

Merck

Shares of Summit Therapeutics Inc. SMMT, +272.06% jumped more than 270% Thursday after the company said its experimental cancer drug outperformed Merck & Co. Inc.'s blockbuster Keytruda in a late-stage clinical trial.

Summit Therapeutics' stock surges as lung-cancer treatment vies with Merck's blockbuster

Summit Therapeutics said on Thursday its experimental therapy to treat patients with a type of lung cancer met the main goal of a late-stage study conducted in China.

Summit Therapeutics cancer therapy succeeds in late-stage China study

MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that the Phase III clinical trial, HARMONi-2 or AK112-303, met its primary endpoint of progression-free survival (PFS). HARMONi-2 evaluated monotherapy ivonescimab against monotherapy pembrolizumab in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors have positive PD-L1 expression (PD-L1 TPS >1%). HARMONi-2 is a single region, multi-cen.

Ivonescimab Monotherapy Decisively Beats Pembrolizumab Monotherapy Head-to-Head, Achieves Statistically Significant Superiority in PFS in First-Line Treatment of Patients with PD-L1 Positive NSCLC in China

Summit Therapeutics' stock is falling sharply for the second consecutive trading day. The sell-off began after the company revealed disappointing late-state data for its lead pipeline candidate.

Why Summit Therapeutics Stock Is Sinking Today

NPMA decision on whether to approve Summit Therapeutics Inc.'s ivonescimab for the treatment of patients with EGFR-mutant metastatic non-squamous NSCLC following TKI progression is expected in Q2 of 2024.

Summit: A Few Catalysts In Q2 Of 2024 To Carry The Tide

Summit Therapeutics specializes in developing innovative therapeutic solutions for oncology and infectious diseases.

Summit Therapeutics' Ivonescimab: Strong Buy Its Dual-Action Approach To Cancer

Summit Therapeutics Inc. (NASDAQ:SMMT ) Q1 2024 Earnings Conference Call May 1, 2024 9:00 AM ET Company Participants Dave Gancarz - Chief Business and Strategy Officer Bob Duggan - Chairman of the Board and Chief Executive Officer Maky Zanganeh - Chief Executive Officer and President Manmeet Soni - Chief Operating Officer and Chief Financial Officer Allen Yang - Chief Medical Officer Conference Call Participants Bradley Canino - Stifel Carter Gould - Barclays Operator Good morning, ladies and gentlemen, and thank you for standing by. My name is Abby, and I will be your conference operator today.

Summit Therapeutics Inc. (SMMT) Q1 2024 Earnings Call Transcript

MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today reports its financial results and provides an update on its operational progress for the first quarter ended March 31, 2024. Operational & Corporate Updates Our operational progress continues with ivonescimab (SMT112), an investigational, potentially first-in-class bispecific antibody combining the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects associa.

Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2024

MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) will host an earnings call to announce its first quarter 2024 financial results and provide an operational update for the Company on Wednesday, May 1, 2024, before the market opens. Summit will host a live webcast of the earnings conference call at 9:00am ET, which will be accessible through our website www.smmttx.com. An archived edition of the session will be available on our website. About Ivon.

Summit Therapeutics to Host First Quarter 2024 Financial Results & Operational Progress Call on May 1, 2024

MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that Mostafa Ronaghi, PhD, has been appointed to its Board of Directors, effective immediately. “We are excited to add Dr. Ronaghi to complement our excellent group of current board members,” stated Robert W. Duggan, Chairman and Chief Executive Officer of Summit. “Mostafa has valuable experience in translating innovative concepts in genomics and sequencing that ultimately lead to.

Summit Therapeutics Appoints Dr. Mostafa Ronaghi, Renowned Executive and Genomicist, to its Board of Directors

MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that it will participate in and present at the Stifel 2024 Targeted Oncology Forum, which will be held virtually April 16-17, 2024. Dr. Maky Zanganeh, Chief Executive Officer and President, Robert W. Duggan, Chairman and Chief Executive Officer, Manmeet Soni, Chief Operating Officer & Chief Financial Officer, Dave Gancarz, Chief Business & Strategy Officer, and Dr. Allen S.

Summit Therapeutics to Present at the Stifel 2024 Targeted Oncology Forum

Illumina

Illumina said on Tuesday Chief Financial Officer Joydeep Goswami would leave the gene sequencing company and would be succeeded by former Summit Therapeutics' executive Ankur Dhingra.

Illumina CFO Goswami to depart, Summit Therapeutics' Dhingra named successor

Joydeep Goswami to serve as advisor through June 30 Illumina reaffirms Q1 2024 and full-year 2024 financial guidance SAN DIEGO , April 9, 2024 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced that Joydeep Goswami has decided to leave Illumina. He will stay on in an advisory role through June 30 to support two new executive management team appointments.

Illumina appoints Ankur Dhingra Chief Financial Officer, Jakob Wedel Chief Strategy and Corporate Development Officer

An analyst initiated coverage of Summit Therapeutics with an enthusiastic buy recommendation. He feels its investigational cancer drug has vast potential.

Why Summit Therapeutics Stock Crushed the Market This Week

MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced promising data for its novel, potential first-in-class investigational bispecific antibody, ivonescimab, that is being presented today at the 2024 European Lung Cancer Congress (ELCC 2024) in Prague, Czech Republic. Two posters featuring updated ivonescimab data will be displayed from 12:00 to 12:45pm Central European Time. The posters will also be made available on our website aft.

Promising Intracranial Anti-Tumor Activity and Safety Data for Ivonescimab in NSCLC Patients with Brain Metastases Featured at ELCC 2024

MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that data for its novel, potential first-in-class investigational bispecific antibody, ivonescimab, will be presented at the 2024 European Lung Cancer Congress (ELCC 2024) in Prague, Czech Republic. Two posters featuring updated ivonescimab data will be displayed on Friday, March 22 from 12:00 to 12:45pm Central European Time. The first poster, “Intracranial Activity of Ivonescimab.

Intracranial Anti-Tumor Activity and Safety of Ivonescimab in NSCLC Patients with Brain Metastases to be Featured at ELCC 2024

NEW YORK , March 11, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Summit Therapeutics Inc. ("Summit" or the "Company") (NASDAQ: SMMT).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Summit Therapeutics Inc. - SMMT

NEW YORK, NY / ACCESSWIRE / March 6, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Summit Therapeutics Inc. ("Summit Therapeutics") (NASDAQ:SMMT) concerning possible violations of federal securities laws. To obtain additional information, go to: https://zlk.com/pslra-1/summit-therapeutics-inc-lawsuit-submission-form?prid=69435&wire=1 or contact Joseph E.

Shareholders that lost money on Summit Therapeutics Inc. (SMMT) should contact Levi & Korsinsky about Securities Fraud Investigation - SMMT

NEW YORK, NY / ACCESSWIRE / March 6, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Summit Therapeutics Inc. ("Summit Therapeutics") (NASDAQ:SMMT) concerning possible violations of federal securities laws. To obtain additional information, go to: https://zlk.com/pslra-1/summit-therapeutics-inc-lawsuit-submission-form?prid=69466&wire=1 or contact Joseph E.

Lost Money on Summit Therapeutics Inc.(SMMT)? Contact Levi & Korsinsky Regarding an Ongoing Investigation

NEW YORK, NY / ACCESSWIRE / March 5, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Summit Therapeutics Inc. ("Summit Therapeutics") (NASDAQ:SMMT) concerning possible violations of federal securities laws. To obtain additional information, go to: https://zlk.com/pslra-1/summit-therapeutics-inc-lawsuit-submission-form?prid=69383&wire=1 or contact Joseph E.

Summit Therapeutics Being Investigated on Behalf of Summit Therapeutics Inc. Investors. Contact Levi & Korsinsky For Details.

NEW YORK, NY / ACCESSWIRE / March 5, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Summit Therapeutics Inc. ("Summit Therapeutics") (NASDAQ:SMMT) concerning possible violations of federal securities laws. To obtain additional information, go to: https://zlk.com/pslra-1/summit-therapeutics-inc-lawsuit-submission-form?prid=69328&wire=1 or contact Joseph E.

Lost Money on Summit Therapeutics Inc.(SMMT)? You May Have Been Affected by Fraud - Contact Levi & Korsinsky

MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that it will participate in and present at the Barclays 26th Annual Global Healthcare Conference, which will be held in Miami Beach, FL, from March 12-14, 2024. Dr. Maky Zanganeh, Chief Executive Officer and President, and Robert W. Duggan, Chairman and Chief Executive Officer, will present on behalf of our organization and provide details regarding the development of our innovativ.

News for Summit Therapeutics Stock (SMMT)